SCHEMBL29317873

SCHEMBL29317873

COc1cc(NC(C)=O)cc(Oc2ccnc3cc(OC)c(C(N)=O)cc23)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 2/20 0.70
KDR P35968 10/20 0.59
MET P08581 6/20 0.59
AURKB Q96GD4 5/20 0.59
TEK Q02763 5/20 0.59
AURKA O14965 4/20 0.59
AXL P30530 5/20 0.58
PDGFRA P16234 4/20 0.54
RET P07949 2/20 0.54
ABL1 P00519 2/20 0.54
RIPK2 O43353 1/20 0.54
ERN1 O75460 1/20 0.54
STK10 O94804 1/20 0.54
MAP3K6 O95382 1/20 0.54
ESR1 P03372 1/20 0.54
PDGFRB P09619 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
KIT P10721 1/20 0.54
BCR P11274 1/20 0.54
FGFR1 P11362 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050049 1.00 DDR2 (0.70) DDR2KDRMETAURKBTEK
SCHEMBL29186593 0.90 KDR (0.69) DDR2KDRMETAURKBTEK
SCHEMBL29317867 0.89 DDR2 (0.79) DDR2KDRMETAXLPDGFRA
SCHEMBL30050336 0.89 DDR2 (0.79) DDR2KDRMETAXLPDGFRA
SCHEMBL29317907 0.89 DDR2 (0.69) DDR2KDRMETAURKBTEK
SCHEMBL30049330 0.89 DDR2 (0.69) DDR2KDRMETAURKBTEK
SCHEMBL31300087 0.84 KDR (0.62) DDR2KDRMETAURKBTEK
SCHEMBL29186517 0.84 KDR (0.59) DDR2KDRMETAURKBTEK
SCHEMBL29317847 0.83 DDR2 (1.00) DDR2KDRMETPDGFRAPDGFRB
SCHEMBL30050488 0.83 DDR2 (1.00) DDR2KDRMETPDGFRAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT DDR2 4341/4885KDR 4885/4885MET 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.